![logo](/logos/VRDN.webp)
Viridian Therapeutics, Inc.
NASDAQ:VRDN
14.09 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Viridian Therapeutics, Inc. |
Symbool | VRDN |
Munteenheid | USD |
Prijs | 14.09 |
Beurswaarde | 900,208,691 |
Dividendpercentage | 0% |
52-weken bereik | 10.925 - 24.18 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Scott D. Myers M.B.A. |
Website | https://www.viridiantherapeutics.com |
An error occurred while fetching data.
Over Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)